Skip to main content

Canada Allergan to recall textured breast implants after Health Canada suspends company license

Allergan Plc said on Tuesday it will voluntarily recall and stop the sale of its Biocell textured breast implants in Canada after the country’s health agency suspended the company’s licenses for the implants, citing increased risk of cancer.

The Botox-maker in December took its textured breast implants off the market in Europe after a French regulatory body ordered a recall.

Textured breast implants, which have a rough surface and are more commonly used in Europe than in the United States, have been linked to a rare type of cancer known as breast-implant associated anaplastic large cell lymphoma (BIA-ALCL).

Story continues below advertisement

The potential risks associated with the implants outweigh their benefits, including the rare but serious risk of BIA-ALCL, Health Canada said on Tuesday.

Health Canada’s decision is in contrast to public rulings and positions by other regulatory bodies around the world, including the U.S. Food and Drug Administration’s (FDA) recent position, Allergan said.

The FDA said in May it would not ban textured breast implants at this time as it investigates the implant and raises awareness related to safety of these devices.

The recall does not impact Natrelle smooth implants, Allergan said, adding it would explore options to appeal the Canadian health regulator’s decision.

Shares of the drugmaker closed down 3% at $131.4 on Tuesday.

Report an error
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Discussion loading ...

Cannabis pro newsletter